CA-CLICKHOUSE
25.6.2024 17:46:36 CEST | Business Wire | Press release
ClickHouse Inc, a leader in real-time analytics, announces the expansion of ClickHouse Cloud to Microsoft Azure, providing users with even more options for deploying and managing their analytics workloads. With this expansion, ClickHouse Cloud is now available on three major cloud service providers.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240625765046/en/
ClickHouse Cloud is now generally available on Microsoft Azure (Graphic: Business Wire)
As organizations increasingly adopt real-time analytics databases in their interactive, data-driven customer-facing applications, as well as in their internal data warehousing and data science workflows, ClickHouse Cloud availability on Azure offers customers greater flexibility and choice. Availability of ClickHouse Cloud in Azure Marketplace allows users to use existing Azure investments and take advantage of integrations with Azure-specific services including Microsoft Power BI and Azure Event Hubs.
“Companies of all sizes trust ClickHouse to gain valuable insights from their data, across a wide variety of use cases,” says Aaron Katz, Co-founder and CEO of ClickHouse, Inc. “This announcement reiterates our vision to bring the best real-time data warehouse to our users regardless of which cloud provider they use.”
“With ClickHouse Cloud generally available on Microsoft Azure, enterprise and digital-native companies alike can take advantage of its breadth of use cases on one of the most open and flexible cloud platforms,” said Erin Chapple, corporate vice president, Azure Core Products and Design at Microsoft. “Mutual customers and partners can now benefit from real-time analytics and business intelligence solutions to gain valuable insights from their data in new ways.”
Public Beta for ClickHouse Cloud on Azure was announced at Microsoft Build in May 2024 and is seeing strong adoption across organizations looking to build real-time analytical applications on top of Azure.
"We are thrilled about the launch of ClickHouse Cloud on Microsoft Azure," said Julian LaNeve, Chief Technology Officer at Astronomer. "Our data platform handles massive volumes of real-time events, and ClickHouse has been instrumental in delivering lightning-fast analytics. With ClickHouse Cloud on Azure, we can deploy and scale effortlessly on Azure's reliable, secure, and scalable infrastructure."
“At BaxEnergy, our mission is to make renewable energy easier, more efficient, affordable, and secure," said Marco Cecconi, Head of R&D of BaxEnergy. “ClickHouse Cloud on Microsoft Azure supports us in conducting advanced analysis on large volumes of data from various renewable energy sources. By generating actionable insights, creating detailed reports, and developing custom dashboards, we empower our customers to achieve better performance and scale their operations effectively. We have been pleasantly surprised by the remarkable speed and flexibility of ClickHouse, and their team has provided us with exceptional dedicated support.”
Some additional benefits of using ClickHouse Cloud on Azure include:
Simplicity. With ClickHouse Cloud, you create your service with a single click. You don't have to worry about the operational complexity of server configurations and cluster topology, shards and replicas, managing backups and restores, durability and fault tolerance, monitoring, or alerts. It just works.
Speed and Scale. ClickHouse Cloud is designed to handle real-time analytics on top of petabyte-scale datasets. There is no need for manual sharding or data movement, as it scales automatically. Our multi-layer cache and other cloud-native performance optimizations ensure impressive query performance for a wide variety of workloads.
Security and Reliability. ClickHouse Cloud has security best practices built in by default. It is configured with network isolation and traffic encryption. ClickHouse builds are additionally hardened, tested, and validated for ClickHouse Cloud. The service is automatically replicated across multiple availability zones for high availability.
Efficiency. ClickHouse Cloud adapts itself to the changing nature of your workloads, scaling up and down as needed. ClickHouse Cloud also takes advantage of shared object storage as its primary storage, while separating compute resources. This dramatically increases flexibility and resource efficiency, delivering industry's best price/performance ratio.
Ecosystem. Easy-to-use integrations allow users to seamlessly ingest data and interface with internal and external systems. A curated set of core and partner integrations vetted to work seamlessly with ClickHouse Cloud are provided in addition to hundreds of community-built integrations. Within the Azure ecosystem, ClickHouse Cloud features turnkey integrations with Azure Event Hubs, Power BI, and Azure Blob Storage.
ClickHouse Cloud offers a 30-day trial that includes $300 free usage credits. To get started, sign up here or subscribe from Azure Marketplace.
About ClickHouse
ClickHouse is a fast, open-source columnar database management system that allows for real-time data processing and analytics. Engineered for high performance, ClickHouse Cloud delivers exceptional query speed, making it an ideal solution for handling large volumes of data. Trusted by leading companies like Lyft, Deutsche Bank and LangChain, ClickHouse Cloud enables businesses to gain critical insights and drive decision-making with its scalable, efficient, and robust data infrastructure. For more information, visit clickhouse.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240625765046/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom